Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements research found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulat… Read More

Elucidating the exact pharmacological system of action (MOA) of naturally occurring compounds can be challenging. Whilst Tarselli et al. (60) created the primary de novo synthetic pathway to conolidine and showcased that this naturally developing compound correctly suppresses responses to both equally chemically induced and inflammation-derived pai… Read More